The classics in perspective.
Panés
Julián
J
Department of Gastroenterology, Hospital Clínic Barcelona, CIBER-EHD, Barcelona, Spain.
Ghosh
Subrata
S
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068582:Certolizumab Pegol; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology; D004359:Drug Therapy, Combination; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects / Q000627:therapeutic use; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D007140:Immunoglobulin Fab Fragments; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D011092:Polyethylene Glycols; D000069285:Infliximab; D000068879:Adalimumab; D000068582:Certolizumab Pegol
N Engl J Med. 2005 Dec 8;353(23):2462-76
16339095
Lancet. 2002 May 4;359(9317):1541-9
12047962
Gastroenterology. 2004 Feb;126(2):402-13
14762776
Clin Gastroenterol Hepatol. 2004 Jul;2(7):542-53
15224278
Gut. 2007 Sep;56(9):1232-9
17299059
Gastroenterology. 2006 Feb;130(2):323-33; quiz 591
16472588
Gastroenterology. 2006 Apr;130(4):1054-61
16618399
Gastroenterology. 2007 Jan;132(1):52-65
17241859